M.E. Allison & CO. Inc. Acquires 285 Shares of Align Technology, Inc. $ALGN

M.E. Allison & CO. Inc. boosted its holdings in shares of Align Technology, Inc. (NASDAQ:ALGNFree Report) by 19.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,750 shares of the medical equipment provider’s stock after acquiring an additional 285 shares during the quarter. M.E. Allison & CO. Inc.’s holdings in Align Technology were worth $331,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ALGN. Ninety One UK Ltd boosted its stake in shares of Align Technology by 58.7% during the first quarter. Ninety One UK Ltd now owns 1,937,555 shares of the medical equipment provider’s stock valued at $307,800,000 after purchasing an additional 716,954 shares during the period. Federated Hermes Inc. lifted its holdings in Align Technology by 510.3% during the 1st quarter. Federated Hermes Inc. now owns 707,514 shares of the medical equipment provider’s stock valued at $112,396,000 after buying an additional 591,588 shares in the last quarter. Mackenzie Financial Corp boosted its position in Align Technology by 4,217.3% in the 1st quarter. Mackenzie Financial Corp now owns 426,205 shares of the medical equipment provider’s stock valued at $67,707,000 after buying an additional 416,333 shares during the period. AQR Capital Management LLC boosted its position in Align Technology by 104.2% in the 1st quarter. AQR Capital Management LLC now owns 404,310 shares of the medical equipment provider’s stock valued at $63,133,000 after buying an additional 206,308 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Align Technology by 32.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 832,313 shares of the medical equipment provider’s stock worth $132,221,000 after acquiring an additional 202,616 shares in the last quarter. Hedge funds and other institutional investors own 88.43% of the company’s stock.

Insider Transactions at Align Technology

In other Align Technology news, CEO Joseph M. Hogan purchased 7,576 shares of Align Technology stock in a transaction dated Friday, August 1st. The shares were acquired at an average cost of $131.49 per share, with a total value of $996,168.24. Following the completion of the transaction, the chief executive officer owned 184,945 shares in the company, valued at approximately $24,318,418.05. This trade represents a 4.27% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.66% of the company’s stock.

Align Technology Price Performance

ALGN opened at $125.79 on Monday. The firm has a market capitalization of $9.12 billion, a PE ratio of 21.21, a price-to-earnings-growth ratio of 1.43 and a beta of 1.70. The business’s 50-day moving average is $135.61 and its two-hundred day moving average is $164.38. Align Technology, Inc. has a 1 year low of $122.00 and a 1 year high of $246.19.

Align Technology (NASDAQ:ALGNGet Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $2.49 earnings per share for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.08). The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1.06 billion. Align Technology had a net margin of 11.04% and a return on equity of 13.36%. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.41 earnings per share. Align Technology has set its Q3 2025 guidance at EPS. As a group, sell-side analysts expect that Align Technology, Inc. will post 7.98 EPS for the current year.

Align Technology declared that its Board of Directors has authorized a stock buyback program on Tuesday, August 5th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the medical equipment provider to purchase up to 2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on ALGN shares. Piper Sandler dropped their price objective on Align Technology from $250.00 to $190.00 and set an “overweight” rating on the stock in a research note on Thursday, July 31st. Zacks Research raised Align Technology from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 30th. Mizuho set a $210.00 price target on Align Technology in a research note on Thursday, July 31st. Jefferies Financial Group reaffirmed a “hold” rating and issued a $140.00 price objective (down from $215.00) on shares of Align Technology in a research note on Friday. Finally, Evercore ISI dropped their target price on shares of Align Technology from $170.00 to $160.00 and set an “outperform” rating on the stock in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $200.00.

Check Out Our Latest Report on Align Technology

Align Technology Company Profile

(Free Report)

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.

Read More

Institutional Ownership by Quarter for Align Technology (NASDAQ:ALGN)

Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.